An inter-laboratory trial of the unified BARGE bioaccessibility method for arsenic, cadmium and lead in soil by Wragg, Joanna et al.
1 
 
An Inter-laboratory Trial of the Unified BARGE Bioaccessibility Method for 
Arsenic, Cadmium and Lead in Soil 
 
Joanna Wragg1, Mark Cave1, Nick Basta2, Esther Brandon3, Stan Casteel4, 
Sebastien Denys5, Christian Gron6, Agnes Oomen3, Kenneth Reimer7, Karine 
Tack5 and Tom Van de Wiele8. 
 
1 British Geological Survey, Nottingham, United Kingdom 
2 School of Environment and Natural Resources, The Ohio State University, Columbus, 
Ohio, 43210-1085, USA 
3 National Institute for Public Health and the Environment, Bilthoven, The Netherlands 
4 College of Veterinary Medicine, University of Missouri, 65205, USA 
5 INERIS, Parc Technologique Alata, Verneuil-en-Halatte, France 
6 DHI Water Environment Health, Horsholm, Denmark 
7 Environmental Sciences Group, Royal Military College of Canada, Kingston, Ontario, 
Canada 
8 Laboratory of Microbial Ecology and Technology, University of Ghent, Ghent, Belgium 
 
ABSTRACT 
 
The Bioaccessibility Research Group of Europe (BARGE) has carried out an inter-
laboratory trial of a proposed harmonised in vitro physiologically based ingestion 
bioaccessibility procedure for soils, called the Unified BARGE Method (UBM). The 
UBM includes an initial saliva phase and simulated stomach and intestine compartments. 
The trial involved the participation of seven laboratories (five European and two North 
American) providing bioaccessibility data for As (11 samples), Cd (9 samples) and Pb (13 
samples) using soils with in vivo relative bioavailability data measured using a swine 
model. The results of the study were compared with benchmark criteria for assessing the 
suitability of the UBM to provide data for human health risk assessments.  Mine waste 
and slag soils containing high concentrations of As caused problems of poor repeatability 
and reproducibility which were alleviated when the samples were run at lower soil to 
solution ratios.  The study showed that the UBM met the benchmark criteria for both the 
stomach and stomach & intestine phase for As. For Cd, three out of four criteria were met 
for the stomach phase but only one for the stomach & intestine phase. For Pb two, out of 
four criteria were met for the stomach phase and none for the stomach & intestine phase.  
However, the study recommends tighter control of pH in the stomach phase extraction to 
improve between-laboratory variability, more reproducible in vivo validation data and 
that a follow up inter-laboratory trial should be carried out. 
 
Keywords: bioaccessibility; bioavailability; inter-laboratory trial; soil; risk assessment; in 
vivo; in vitro 
 
1. Introduction 
 
The Bioaccessibility Research Group of Europe (BARGE, 
http://www.bgs.ac.uk/barge/home.html) is a European network bringing together 
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international institutes and research groups to study human bioaccessibility of priority 
contaminants in soils via the gastrointestinal (GI) tract.  The key contaminants included in 
this work are arsenic (As), lead (Pb) and cadmium (Cd) as they are potentially harmful to 
human health (ATSDR, 2007b; ATSDR, 2007a; ATSDR, 2008) and the most common 
elements undergoing bioaccessibility research (Smith et al., ; Ruby et al., 1993; Ruby et 
al., 1996; Albores et al., 2000; Oomen et al., 2002; Marschner et al., 2006; Chan et al., 
2007; Datta et al., 2007; Drexler and Brattin, 2007; Finzgar et al., 2007; Hansen et al., 
2007; Juhasz et al., 2007a, 2007b; Ljung et al., 2007; Sarkar et al., 2007; Subacz et al., 
2007; Turner and Ip, 2007; Van de Wiele et al., 2007; Beak et al., 2008; Moseley et al., 
2008; Girouard and Zagury, 2009; Morman et al., 2009; Nagar et al., 2009; Poggio et al., 
2009; Smith et al., 2009; Zhang et al., 2009; Demetriades et al., 2010; Juhasz et al.2010).  
These contaminants are associated with a legacy of industrial activities (Gasser et al., 
1996; Razo et al., 2006; Rieuwerts et al., 2006; Basta et al., 2007; Laird et al., 2007; 
Morrison and Gulson, 2007; Bosso and Enzweiler, 2008; Bosso et al., 2008; Romero et 
al., 2008; Caboche et al.,2010; Meunier et al.,2010; Roussel et al., 2010) and natural 
background geology (Fendorf et al., 2004; Koch et al., 2005; Nathanail et al., 2005; 
Palumbo-Roe et al., 2005; Wragg, 2005; Cave et al., 2007; Juhasz et al., 2007b; Wragg et 
al., 2007), which are of concern to a number of the countries participating in BARGE.   
 
The accurate determination of bioaccessibility has the potential to make a significant 
impact on current risk assessment practice. BARGE has been involved in comparing and 
evaluating the physico-chemical processes within the many models and systems that have 
been developed over the years to measure bioaccessibility and contaminant exposure e.g. 
(Oomen et al., 2002; Basta et al., 2007; Cave et al., 2007; Chan et al., 2007; Gal et al., 
2007; Gron et al., 2007; Ljung et al., 2007; Nathanail and Smith, 2007; Palumbo-Roe and 
Klinck, 2007; Subacz et al., 2007; Van de Wiele et al., 2007; Wragg et al., 2007; Wragg 
and Klinck, 2007). A priority objective is to provide robust and defensible data on 
bioaccessibility that can be used in human health risk assessments and policy making. 
The concepts of bioaccessibility and oral bioavailability are fundamentally important for 
quantifying the risks that are associated with oral exposure to environmental 
contaminants. Bioaccessibility refers to the fraction of a contaminant that is released from 
soil into solution by digestive juices. It represents the maximum amount of contaminant 
that is available for intestinal absorption. In general, only a fraction of these bioaccessible 
contaminants can be absorbed by the intestinal epithelium. Inorganic contaminants are 
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subsequently transported to the liver via the portal vein for biotransformation. The 
fraction of parent compound that reaches the systemic circulation is referred to as the 
bioavailable fraction. Given the fact that bioaccessibility is one of the principal factors 
limiting the bioavailable fraction, it is an important parameter to measure for risk 
assessment purposes. 
 
Bioavailability data from actual human soil feeding tests is scarce (Maddaloni et al., 
1998; Stanek et al.,2010) and although in vivo animal studies are have been carried out, 
these are, in general costly, time consuming, have ethical constraints and there is usually 
only a limited amount of soil available (Freeman et al., 1992; Freeman et al., 1993; Ruby 
et al., 1993; Freeman et al., 1995; Golub et al., 1999; Rodriguez et al., 1999; Ellickson et 
al., 2001; Schroder et al., 2003; Schroder et al., 2004; Marschner et al., 2006; Makris et 
al., 2008; Bannon et al., 2009; Nagar et al., 2009) and Juhasz et al (2007a, 2008, 2009a, 
2009b). An alternative is the application of in vitro models that simulate the GI tract. 
These screening methods can be used to measure the bioaccessible contaminant fraction, 
as bioaccessibility is an important parameter prior to bioavailability. A number of in vitro 
bioaccessibility tests for mimicking human ingestion have been reported in the literature 
and have been comprehensively reviewed (Wragg and Cave, 2003; Dean and Ma, 2007). 
Of these, there are four batch extraction methods which are most commonly used : the 
physiologically based extraction test (PBET) originally developed by Ruby (1996); the in 
vitro gastrointestinal method (IVG) (Rodriguez et al., 1999); the Dutch National Institute 
for Public Health and the Environment method (RIVM) (Versantvoort et al., 2004) which 
is mainly used in Europe; and the relative bioaccessibility leaching procedure (RBALP) 
which was developed specifically for Pb in soils (Drexler and Brattin, 2007). The PBET, 
IVG, and RIVM methods use extraction media that closely mimic the chemical 
environment of the human gastrointestinal system i.e. they are physiologically based, 
whereas the RBALP uses physiologically relevant pH of the stomach but uses a glycine 
buffer as the extraction medium. 
 
As a result of research carried out by BARGE and other research groups it was clear that 
the different bioaccessibility tests showed similar trends when used on the same soil 
samples, but the different operating conditions for each test produced widely ranging 
bioaccessibility values between the methods (Oomen et al., 2002; Saikat et al., 2007; Van 
de Wiele et al., 2007; Juhasz et al., 2009a; 2009b). For example, in a study of five 
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different methods on three test soils (Oomen et al., 2002)a wide range of bioaccessibility 
values were found: for As 6-95%, 1-19%, and 10-59%; for Cd 7- 92%, 5-92%, and 6-
99%; and for Pb 4-91%, 1-56%, and 3-90%. This made comparison of data difficult to 
carry out in a subjective manner causing regulators and risk assessors some concern 
(Environment Agency, 2005b; Environment Agency, 2005a; Environment Agency, 2007; 
Richardson, 2008; Scheckel et al., 2009; Latawiec et al., 2010). To overcome this 
problem, BARGE undertook a joint decision to progress the development of a 
harmonised in vitro bioaccessibility method.   
 
The main criteria for the test were: 
 
i) It should be physiologically based, mimicking the human GI physico-chemical 
environment in the stomach and small intestine. This should not only help to 
obtain good agreement with in vivo data but would also enhance public 
understanding of the test; 
 
ii) It should represent a conservative case; 
 
iii) There should be one set of conditions for all potentially harmful elements (PHE) 
being studied; 
 
iv) It must be demonstrated that the test is a good analogue of in vivo conditions; and 
 
v) The test must be able to produce repeatable and reproducible results within and 
between testing laboratories. 
 
The chosen method was that previously published by researchers at the Dutch Institute of 
Public Health, the RIVM (Oomen, 2000; Oomen et al., 2002), as this was considered to 
be the most suitable static or batch method available, and therefore more likely to be 
adopted by testing laboratories. The RIVM methodology has also gained acceptance by 
regulators in both the Netherlands and Denmark. Modifications were made to the RIVM 
methodology to ensure adequate conservatism, that the in vitro test was robust and 
applicable to the different soil types found in a range of different countries.  
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2. Method performance and benchmarks 
 
The evaluation of the UBM was undertaken by means of an international inter-laboratory 
exercise. For the method to be ‘fit for purpose’ the bioaccessibility would need to pass 
quantitative tests on how well the test could be validated by an in vivo result and how 
reliably the test could be carried out (repeatability and reproducibility). A validation study 
of a simple one compartment bioaccessibility test (not physiologically based) for Pb has 
recently been carried out (Drexler and Brattin, 2007) and shows some very impressive 
statistical performance figures for both validation and reliability.   
 
Although there is not much literature on acceptability criteria for in vitro/in vivo 
validation of bioaccessibility tests in soil, there is an equivalent in vitro/in vivo correlation 
test (IVIVC) used widely in the pharmaceutical industry. The IVIVC test is a tool 
designed to correlate in vitro and in vivo drug release (Emami, 2006).  The bioavailability 
of the administered drug, measured by the fraction of the drug absorbed into the human 
body (equivalent to the animal testing data for metal uptake from soil) is correlated to the 
in vitro bioaccessibility measured by a dissolution test (equivalent to the UBM 
bioaccessibility test for soil). The US Federal Drug Administration has set out guidelines 
for the acceptability of results (1997) which include: 
i) A linear relationship with slope of unity, if possible, is preferred, to show that the 
in vitro dissolution is representative in vivo absorption; 
ii) The relative standard deviation (RSD) for the in vitro measurement of a single 
sample should be less than 10% (repeatability); 
iii) The prediction error of the in vivo absorption from the in vitro dissolution test 
should not exceed 15% for each formulation (sample). 
 
This provides a basis for setting up performance criteria for the soil bioaccessibility 
validation. Pharmaceutical formulations are, however, far more homogeneous and less 
complex than soil samples and therefore these criteria may be too stringent for soil 
testing. It is necessary to go to the literature to look at the repeatability of inter-laboratory 
trials on soil testing. Drexler’s soil bioaccessibility inter-laboratory trial (2007) reported a 
repeatability of 4% and reproducibility of 6% (measured as the percent RSD). There are 
not many other inter-laboratory studies for bioaccessibility testing available; however, 
there are instances of laboratory trials on soils where PHEs are extracted using different 
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reagents to determine their solid phase distribution and speciation, which is similar to the 
UBM bioaccessibility test. In the inter-laboratory trial for the European Community 
Bureau of Reference (BCR) sequential extraction test on a lake sediment (Quevauviller, 
2002) the between-laboratory repeatability for Cd was 15, 13 and 75% RSD for three 
extraction steps and for Pb 19, 5.4 and 29% RSD (As was not determined). Another inter-
laboratory trial on soils (Nagourney et al., 2008) used a standard extraction test to 
determine the CrVI content of a reference soil giving an inter-laboratory RSD of ~20%. 
This clearly shows that between-laboratory repeatability in soil extraction studies of 
PHEs can be highly variable. 
Using the combined information from IVIVC and from soil extraction literature the 
following soil bioaccessibility testing validation criteria (benchmark criteria) are 
proposed: 
i) There should be a linear relationship between the relative bioaccessibility and the 
relative bioavailability where relative bioavailability/bioaccessibility refers to the 
bioavailable/bioaccessible fraction of the contaminant in the soil relative to the 
bioavailability/bioaccessibility of a soluble salt of the contaminant. A slope of 
unity, if possible, is preferred, to show that the in vitro bioaccessibility is 
representative of the bioavailability study; the linear relation should be 
demonstrated by a very strong correlation coefficient (r >0.8 or r2 >0.6) and a 
slope >0.8 and < 1.2 
ii) The within-laboratory repeatability should be ≤10% RSD 
iii) The between-laboratory reproducibility should be ≤ 20% RSD   
 
3. Materials and methods 
3.1. Samples under investigation 
The materials under investigation included slag materials, soils, river sediments and 
house dusts containing in vivo data for As, Cd and Pb. A number of the donated soils had 
previously been studied in bioaccessibility investigations and the resulting data reported 
in the peer reviewed literature (Rodriguez et al., 1999; Rodriguez et al., 2003; Schroder et 
al., 2003; Schroder et al., 2004; Basta et al., 2007). Where information on the source of 
the material, contaminants and subsequent testing data was not readily available in the 
literature, it was provided by the donor of the individual samples. In addition to in vivo 
tested soils as a primary source of contaminated material, the evaluation of the UBM also 
included the two National Institute of Standards and Technology (NIST) standard 
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reference materials (SRMs), 2710 and 2711, which have been studied by various workers 
in relation to their bioaccessible contaminant contents (Ellickson et al., 2001; Cave et al., 
2003; Schroder et al., 2004). and a soil (BGS 102), containing naturally elevated As 
concentrations, prepared by the British Geological Survey (BGS) specifically for the 
purposes of bioaccessibility testing (Wragg, 2009). Table 1 summarises the materials 
studied in the inter-laboratory trial, including the material type, references to published 
information and the total and relative bioavailable data available. 
 
3.2. In vitro bioaccessibility method 
The in vitro UBM, was a physiological GI simulation based on the methodology utilized 
at the RIVM, previously described by Oomen et al (2002). The procedure was carried out 
according to the schematic in Figure 1 and has been described in full in other publications 
(Wragg et al., 2009; Roussel et al., 2010).  The UBM was carried out at 37C (body 
temperature), at a final soil:solution ratio of 1:100 (g ml-1) with end over end rotation at 
30 rpm.  The simulation consisted of three stages: the mouth, stomach and small intestinal 
cavities at a stomach pH of 1.2 and an intestinal pH of 6.3 under fasting conditions, which 
produced two individual extracts per test sample for analysis. The sample known as 
‘stomach’ phase consisted of an extraction solution removed from the system after 
simulation of the mouth (utilizing simulated salival fluid) followed by the stomach 
(utilizing simulated stomach fluid) compartments. The sample known as ‘stomach & 
intestine’ represented the extraction solution removed after simulation of the mouth, 
stomach and small intestine (utilizing simulated saliva, stomach, bile and duodenal fluids) 
phases of the system. The chemical constituents included in each phase were the same as 
those previously reported (Oomen et al., 2002), with the exception the duodenal fluid, 
which contained an increased concentration of sodium hydrogen carbonate (5.607 g l-1 
compared with 3.388 g l-1 in the original methodology). The increased sodium hydrogen 
carbonate concentration was employed to compensate for the lower, but still 
physiologically acceptable, stomach pH used in the method (1.2 compared with 1.5 used 
by the RIVM method). The reason for reducing the pH to 1.2 was based on preliminary 
studies where calcareous soils were found to cause difficulties in maintaining a low pH in 
the stomach phase. Reducing the pH to a lower but still physiologically acceptable value 
of 1.2 helped to alleviate this practical difficulty.  
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In summary, 9.0 ml of salival fluid was added by pipette to 0.6 g of test material for both 
the ‘stomach’ and the ‘stomach & intestine’ extractions; the extraction vessels were 
capped and shaken manually for 30s.  To each test aliquot, 13.5 ml of gastric fluid was 
added and the extraction vessels were capped and placed into an extractor and incubated 
using end-over-end rotation, at 37 ± 2°C for 1 hour.  At the end of 1 hour both the 
‘stomach’ and ‘stomach & intestine’ extracts were removed from the incubator and the 
pH of the suspension measured.  If the pH of the suspension was measured at 1.2 – 1.7, 
the ‘stomach’ phase extract was deemed complete and the ‘stomach & intestine’ extract 
was taken forward to carry out the intestinal digestion phase.  If the pH tolerance was not 
met and there was sufficient solid material available, the UBM extraction was repeated 
and the pH was adjusted to between 1.2 – 1.7 using up to 1.0 ml of concentrated HCl 
(37% or  12 N).  If the pH criterion was met, the ‘stomach’ phase extract was centrifuged 
at 3000 g for 5 minutes and a 1.0 ml aliquot preserved by the accurate addition 9.0 ml of 
0.1M HNO3.  To continue the extraction and carry out the ‘stomach & intestine’ phase, 
27.0 ml of duodenal fluid and 9.0 ml of bile fluid were added by pipette, the samples re-
capped, manually shaken for 30s and the pH checked to ensure that it was 6.3 ± 0.5.  If 
the pH criterion was not met, the pH was adjusted by the dropwise addition of 37% HCl, 
1M or 10M NaOH as required and then replaced in the incubator at 37°C and rotated for a 
further 4 hours.  At the end of the intestinal incubation period, the pH was recorded and 
the suspensions centrifuged for 5 minutes at 3000 g.  An aliquot of the supernatant was 
collected and preserved in the same manner as the ‘stomach’ phase extractions.  Both 
extraction phases were stored at 1 - 8°C.  For both the ‘stomach’ and ‘stomach & 
intestine’ phases of the UBM, all contributing laboratories made a record of any 
additional HCl or NaOH adjustments made to either phase. Because of the small amount 
of material available for the inter-laboratory trial, it was not possible for all contributing 
laboratories to carry out repeat extractions because of pH tolerance failures, and therefore 
some data was reported that was outside the scope of the required tolerances.  Two 
laboratories also carried out the UBM extractions for the As soils at a lower soil to 
solution ratio of 1:1000 g ml-1.  Because the bioaccessible element content of BGS 102 
was assumed to be relatively low compared with the in vivo validation soils, based on the 
total element concentration data available, the contributing laboratories provided an 
additional 10.0 ml aliquot of unpreserved and therefore undiluted ‘stomach’ and ‘stomach 
& intestine’ extract for analysis. 
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Prior to evaluation of the UBM, a detailed Standard Operating Procedure (SOP) was 
agreed by all BARGE laboratory participants (the BGS, DHI, INERIS, Ohio State 
University, RIVM, the Royal Military College of Canada (RMC) and the University of 
Ghent) (Wragg 2009). The lead laboratory (BGS) issued instructions to all participating 
laboratories, which included a list of materials to be investigated and the number of 
duplicate, blank and spike extractions expected. To ensure standardisation of the 
procedure and reduction in uncertainty estimates, all equipment and reagents were 
sourced by each laboratory from the same suppliers. Where a contributing laboratory was 
unable to obtain the required reagents, the lead laboratory satisfied the requirement by 
supplying said laboratory. Polypropylene tubes with screw top lids (101 x 16.5mm, with a 
capacity of 13 ml) were provided to each laboratory for sample storage and transportation 
and a simple digestion and analysis that was carried out by the lead laboratory. The lead 
laboratory carried out digestion of the extracts in order to re-solubilise any analytes 
sorbed to the surface of the tubes during transit and storage, and to ensure that all samples 
were of the same acidic matrix for analysis, regardless of minor operational differences 
applied in the individual laboratories.  To each digestion tube 1.0 ml of AristaR grade ® 
concentrated HNO3 and 1.0 ml of 70 % v/v H2O2 were added by auto-pipette and the 
tubes loosely capped and placed in a temperature controlled hot-block for 3 hours at 70 
°C. After cooling the samples were capped tightly and stored at 1 – 8 °C prior to analysis. 
Full details of the selection criteria for the sample tubes and the digestion procedure have 
been fully described by Wragg et al. ( 2009). 
 
3.4. Bioaccessibility extract analysis 
The bioaccessible As, Cd and Pb content of each extract provided was determined 
directly by a Varian/Vista AX CCD simultaneous instrument with dedicated Varian SPS-
5 Auto-sampler and PC running the latest version of ICP Expert software supplied by the 
instrument manufacturer, according to the operating conditions previously described 
(Cave and Wragg, 2002; Wragg, 2005). Each sample was introduced with 1% caesium 
chloride (as an ionisation buffer) via a peristaltic pump into a glass concentric slurry 
nebuliser connected to a cyclonic action spray chamber. Analysis was carried out on ~2.5 
ml of the UBM digested ‘stomach’, ‘stomach & intestine’ extraction solution. Arsenic, 
Cd and Pb were determined in the UBM extracts after calibration using a minimum of 5 
mixed element standards in a 1% HNO3 matrix.  The 'inductively coupled plasma-optical 
emission spectrometer (ICP-OES) was calibrated to concentrations up to 100 mg l-1 for 
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As and Pb and 10 mg l-1 for Cd and re-calibrated after not more than 125 unknown 
samples. Two quality control standards, at ~10 and 75% of the calibration range, were 
analysed after each calibration, after no more than ten unknown solutions during the run 
and at the end of each run to check for drift. As the bioaccessibility matrix had been 
diluted to a ratio of 1:10 (g ml-1) with 0.1M HNO3 prior to shipping, and digested in 
mixed HNO3/H2O2 on arrival at the lead laboratory no further matching to the calibration 
or QC standards was deemed necessary. All reported measurements, as mg l-1, were based 
on the average of three 10 second replicate measurements. All element concentrations 
quoted have been converted into mg kg-1 extracted from the solid. The analysis of 
unpreserved BGS 102 was carried out using a Thermo Elemental ExCell quadrupole ICP-
MS instrument in combination with a Cetac ASX-510 autosampler, according to the 
operating conditions previously described by Watts et al. (2008). The instrument was 
calibrated at the beginning of each analytical run using standards prepared from certified 
Claritas PPT® (Spex CertiPreP) multi-element solutions in the range 0 to 50 µg l-1. In 
addition, 10 µg l-1 mixed element standards were inserted at regular intervals throughout 
the analysis run and used to correct for any drift in instrument sensitivity. Indium and 
rhenium were added to all solutions via a T-piece connection and used as internal 
standards to correct for any matrix suppression. Multi-element QC standards, containing 
As, Cd and Pb, were analysed after no more than every 20 unknown samples. Because of 
limited sample volume, all of the samples were diluted by a factor of two with 1% HNO3 
prior to analysis. 
 
3.5.  Quality Control 
In order to gain an insight into the within-laboratory repeatability, duplicate UBM 
extractions of each test material, commonly employed reference materials normally used 
for their total concentrations, blanks and spikes were requested from each participating 
laboratory. However, due to time constraints this was not possible for all participating 
laboratories. The reference material QC samples were either the NIST 2710 or 2711 SRM 
(or both where possible) and the BGS 102 As bioaccessibility guidance soil (Wragg, 
2009). The blank QCs consisted of the individual ‘stomach’ or ‘stomach & intestine’ 
matrix taken through the entire UBM in vitro procedure, prior to submission for analysis, 
to account for As, Cd and Pb contamination from the chemicals and the extraction 
equipment in use. The spike QCs were individual 100 mg l-1 spiking solutions of As, Cd 
and Pb, provided by the lead laboratory, with instructions for the preparation of a mixed 
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spiking solution for extraction in order that each analyte was present in solution, in each 
phase (‘stomach’ or ‘stomach & intestine’) at 0.1 mg l-1, after sample preservation. The 
spiking solutions were extracted with no test material present to check the percentage (%) 
recovery of the extraction method, i.e. that no analyte was adsorbed to the extraction 
tubes or lost during the extraction procedure. 
 
3.6. Statistical data analysis 
The analytical performance characteristics of the bioaccessibility measurement 
(repeatability and reproducibility) were determined in the collaborative study using the 
procedure described in ISO Standard 5725-2 (ISO). Outlier testing using Grubbs’ test 
(Grubbs, 1950) and Cochran’s test (Snedecor and Cochran, 1980) were carried out in the 
R statistical programming language using the outliers package (R Development Core 
Team, 2007) and the outlier removal rules specified in ISO Standard 5725-2 were 
applied. Repeatability and reproducibility calculations were carried out in MS Excel™. In 
addition to the ISO 5725-2 statistical calculations, the in vivo relative bioavailability data 
is plotted against the relative bioaccessibility data to show the relationship between the in 
vivo and the in vitro measurements. Linear regression analysis was carried out using 
Theils method (Theil, 1950; Glaister, 2005) that makes no assumption about the errors on 
the x and y axes and is robust to outliers. Confidence limits on the regression line were 
calculated using ten thousand Monte Carlo simulations using the uncertainties on the 
relative bioaccessible and relative bioavailable data. The procedure was implemented in 
the MATLAB programming language.   
 
4. Results 
The mean relative bioaccessibilities and associated relative standard deviations for As, Cd 
and Pb for each sample in each compartment (along with the additional data for the lower 
soil to solution ratio for As) are given in Tables 2 and 3. 
 
4.1. Quality Control 
Each participating laboratory supplied a minimum of three blank extraction samples from 
each of the UBM phases, under the standard (1:100 g ml-1) extraction conditions. For the 
‘stomach phase’ extractions, all data for As was returned at below the limit of 
quantification (<6.75 mg kg-1); however, for Cd, one data point for one laboratory was 
within 2 times the reporting limit (<0.90 mg kg-1) and, for Pb a second laboratory 
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returned two blank sample values within 3 times the reporting limit (<0.225 mg kg-1). For 
the ‘stomach & intestine phase’ all of the blank extraction samples returned values less 
than the reporting limit for As (<17.6 mg kg-1), Cd (<2.34 mg kg-1) and Pb (<5.85 mg 
kg-1). Where ICP-AES values for test sample extractions were returned below the 
reporting limit or the increased soil to solution ratio of 1:1000 (g ml-1) was employed, the 
samples were analysed by ICP-MS because of its increased sensitivity and lower 
reporting limits. The data from the extraction blanks provides a good indication that the 
reagents or equipment used in the UBM methodology did not contribute As, Cd or Pb to 
the sample data.   
 
Six of the seven participating laboratories provided a minimum of two mixed element 
spike extracts for each phase of the UBM, under the standard (1:100 g ml-1) extraction 
conditions, for analysis. One laboratory was unable to provide any spike extracts. Figure 
2, a box and whisker plot, summarises the range of mean percentage As, Cd and Pb spike 
recovery values in each of the two UBM phases for the participating laboratories. Figure 
2 shows that, for the ‘stomach’ phase of the extraction, the As, Cd and Pb recovery was 
105 ± 10 %, and that there was a wider spread in the data for the ‘stomach & intestine’ 
phase extractions. For As and Cd in the ‘stomach & intestine’ phase, Figure 2 indicates an 
increased spread in the % recovery of ~80 – 110 %, compared with the ‘stomach’ phase, 
although both the median As and Cd recoveries of ~100 and 90% respectively are 
considered acceptable. The percentage spike recovery for Pb in the ‘stomach & intestine’ 
phase ranges from ~55 to 105% (Figure 2), with a median value of ~75%. The behaviour 
of Pb and Cd is strongly pH dependent, with higher solubility in acidic conditions and 
complexation by pepsin or chemical precipitation of metals in an increased pH 
environment such as the gastro-intestinal compartment (Ellickson et al., 2001; Gron and 
Andersen, 2003).  This is not observed in the case of elements that form anions in 
solution and is consistent with previous studies for As (Oomen et al., 2006).  For the 
extractions carried out at the decreased soil:solution ratio, As spike recoveries of 100 and 
99% for the ‘stomach’ and ‘stomach & intestine’ phases respectively were returned. 
Table 4 gives a summary of the mean bioaccessible values for each element in each 
compartment for the quality control reference soils along with the within-laboratory 
repeatability and the overall between-laboratory reproducibility expressed as the relative 
standard deviation.  This data cannot be used to check accuracy as there are no certified 
bioaccessible values, but they serve to give an idea of the uncertainty in the results both 
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within and between laboratories for milled and well homogenised soils.  BGS102 data 
tends to have higher within and between-laboratory variability compared with the two 
NIST soils. This is probably due to the relatively low concentrations of bioaccessible As, 
Cd and Pb in this soil.  After a dilution of 100 in the extraction stage, and a further 
dilution of 10 in the preservation stage the As, Cd and Pb concentrations in solution are 
likely to be at or approaching detection limits for the ICP-AES instrument used for the 
analysis of the extracts.  For NIST 2710 and NIST 2711, the bioaccessible concentrations 
of As, Cd and Pb are significantly higher than BGS 102 so variability from being close to 
detection limits should not be a problem. The variability of results for the NIST soils is 
inconsistent from being very good (~3% RSD for Cd and Pb and in NIST 2711 in the 
stomach phase) to poor (94.6% in NIST 2711 for Pb in the stomach phase). Some of the 
reasons for these differences are discussed in more detail in sections 4.5 to 4.7 but this 
exercise suggests the variability is method related and not down to sample heterogeneity. 
 
4.2. Total element data 
The total As, Cd and Pb concentrations in the test samples were obtained from previously 
published data using USEPA method 3050 (Schroder et al., 2003; Schroder et al., 2004; 
Basta et al., 2007) given in Table 1.  However, the BGS laboratories undertook trial 
digestions of the As samples, which when subjected to a mixed acid digestion (HF, HNO3 
and HClO4) explosive ejections of sample and reagents from the reaction tube were 
observed. This indicated that the mixed acid digest employed was not suitable for these 
samples but served to illustrate the unusual geochemistry of these materials, thought to be 
due to the presence of high concentrations of elemental sulphur.  
4.3. pH tolerances 
The UBM protocol (Figure 1) requires that the pH of the individual extracts are checked 
at the end of the ‘stomach’ and ‘stomach & intestine’ phases and the start of the ‘stomach 
& intestine’ extraction phase to ensure that acceptable pH values are achieved.  Figure 3 
and 4 summarise the distribution of the pH data obtained for the end of the ‘stomach’ 
phase of the UBM, as a box and whisker plot.  Figure 3 shows that the end ‘stomach’ 
phase pH tolerance criteria (1.2 to 1.7) for the As soils was met by the contributing 
laboratories for the majority of the test samples.  However, for samples As 6 and 7 a wide 
range of pH values were observed, ~1.2 to 4.0 and 4.7 respectively. Outliers (denoted as 
solid black crosses), outside of the pH tolerance were observed for sample As 8 (~pH 
2.75 and 3.5), similarly for sample As 9 (pH 2.25) in addition to the maximum value for 
14 
 
this sample (~2.0). A similar trend was observed for pH measurements made in both 
compartments during the ‘stomach & intestine’ extract for the As soils (data not shown), 
where samples As 6 and 7 were outside of the required pH tolerances. For the materials 
contaminated with Cd and Pb (Figure 4), samples NBR-255B-04, NBR-256-04, NBR-
267-04, NBPb9 and NBPb11 all had end ‘stomach’ phase pH’s in the range c. 4.0 – 5.0, 
sample BV2TM1 ranged between 1.2 and 3.25 and the maximum pH’s of samples BV1A, 
BV1B and DNR5-1 was 1.8, for both the ‘stomach’ and ‘stomach & intestine’ 
extractions. As there was a limited mass of NBR-255B-04, NBR-256-04, NBR-267-04, 
NBPb9 and NBPb11, these samples were only extracted by one laboratory. 
 
4.4. Validation and reliability of the test 
The relative bioavailability data obtained from the in vivo studies for the three elements 
have been obtained by taking the ratio of the amount absorbed from the soil to the amount 
absorbed from a completely soluble salt of the element.  In order to make a meaningful 
comparison the absolute bioaccessibility as measured by the UBM in vitro test (amount of 
element extracted from the soil expressed as a percentage of the total element in the soil) 
was converted to a relative bioaccessibility by dividing the absolute bioaccessibility of the 
contaminant in the soil by the absolute bioaccessibility of the completely soluble salt. The 
bioaccessibility of the same salts used in the in vivo studies (As in Na-arsenate, Cd in Cd-
chloride and Pb in Pb-acetate) were measured using the same UBM procedure used for 
the soils. In the gastric phase, the absolute bioaccessibility values were 99 ± 2% and 98 ± 
3% for Pb in Pb-acetate and Cd in Cd-chloride, respectively.  For As in Na-arsenate 
bioaccessibility was 95 ± 3%.  This showed that all three elements were either 
indistinguishable or within 2% of being 100% bioaccessible for the reference compounds 
in this compartment. In contrast, in the intestinal phase Pb and Cd had reduced absolute 
bioaccessibility giving values of 66 ± 3% and 68 ± 3% respectively; however, the As 
bioaccessibility remained high at 92 ± 4% . The reasons for this are related to the 
solubility and stability of Cd and Pb in the higher pH solutions as discussed earlier 
(Ellickson et al., 2001; Gron and Andersen, 2003).  
Table 5 gives the values of the assessment criteria (defined at the end of section 2) for 
each element and each of the simulated GI compartments.  The grey highlighted values 
indicate where the required benchmark value was achieved. Figure 5 shows plots of the % 
relative bioavailable values versus the % relative bioaccessible values, showing error bars 
on both axes along with the Theil line of best fit, the 90% confidence interval for the line 
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and the line of equivalence. Figure 6 summarises the within and between-laboratory RSD 
values.  
4.5. Arsenic  
Table 5 shows that correlation between in vitro and in vivo data is strong for both 
compartments, but the slope of the lines are low. Figure 5 show there are some very large 
uncertainty bars for some samples on both the bioavailable and bioaccessible data. Table 
5 and Figures 5(a), 5(b), 6(a) and 6(b) show that although the within-laboratory 
repeatability meets the benchmark criteria, the between-laboratory data for both 
compartments does not. Figure 3 shows that samples As 6 and As 7 deviated significantly 
from the target pH range compared with the other samples which may have caused poor 
reproducibility. Figure 5(a), however, does not show that these samples have higher 
bioaccessibility uncertainties. Leaving sample As 6 and As 7 out of the calculations for 
benchmark data for Table 5 did not have any significant effect on the assessment criteria 
and the data for these two points were therefore retained. In a previous study (Basta et al., 
2007) using soils As 1 to As 10 (Table 1) to test a different in vitro bioaccessibility 
method (the IVG method) the soils As 1 to As 4 are identified as being contaminated with 
a calcine waste material and samples As 6 to As 10 oxidized waste material (slag) 
generated from the roasting and/or smelting of arsenopyrite ore.  Examination of Figure 5 
(a and b) and Table 2 clearly shows that the slag samples, that have the lower total As and 
higher bioaccessibilities have much poorer reproducibility (high average standard 
deviation ~12% relative bioaccessibility) compared with the calcine samples (average 
standard deviation ~0.8% bioaccessibility) suggesting that this is caused by the 
geochemistry of these samples. Additional geochemical data on these samples (Rodriguez 
et al., 2003) shows that the calciner samples have relatively acid soil pH (2.6 – 3.1) and 
low Ca concentrations (11.7-18 g kg-1) compared with the slag soils (soil pH 7.1-7.4 and 
Ca concentrations of 60.7-121 g kg-1). The samples with the highest Ca concentrations 
(As 6 and As 7, 121 and 96.4 g kg-1 respectively) are the samples with the poorly 
controlled pH tolerance for the ‘stomach’ phase of the UBM (Figure 3). This suggests 
that the poorer between-laboratory reproducibility on the iron slag samples is a function 
of their high buffering capacity highlighting the need for tighter control limits on the 
‘stomach’ phase.  Comparing the absolute % bioaccessibilities, obtained by the UBM 
with the IVG previous study (a method that uses a soil to solution ratio of 1:150, a 
stomach pH of 1.8 for 1 hr and an intestinal ph of 5.5 for 1 hr) shows that there is very 
good agreement between the two data sets.  For the ‘stomach’ compartment (a simple 
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linear regression with the UBM on the x-axis and IVG on the y axis gives rsquare=0.99, 
slope=1.15 and intercept-2.2). For the ‘stomach & intestine’ compartment, however, 
agreement is poor (rsquare = 0.38, slope = 2.3, intercept = -2.6) this is probably due to the 
lower pH (5.5) and shorter reaction time used in the IVG method.     
In summary, the data for the 1:100 g ml-1 soil:solution ratio for these test materials appear 
to show poor reproducibility for the slag samples and low relative bioaccessibility values 
as compared with the relative bioavailability (Figures 5(a) and Figure 5(b) but the 
stomach compartment data show close agreement with an independent bioaccessibility 
test.  Additional extractions at the lower soil to solution ratio (1:1000 g ml-1) were carried 
out on nine of the original samples (the two Aberjona river samples were not extracted at 
this lower soil to solution ratio due to lack of material).  At the lower ratio there was 
much improved agreement with relative bioavailability.. The r-square values in Table 5 
for this ratio indicate a strong correlation with relative bioavailable As, with the slopes of 
the lines meeting the benchmark criteria. Figures 5(c) and 5(d) show the uncertainties on 
the bioaccessibility values to be much reduced compared with the 1:100 g ml-1 solid to 
liquid ratio, although only two laboratories have contributed data for the high dilution 
conditions. Table 5 and Figures 6(c) and 6(d) show that the within-laboratory 
repeatability meets the benchmark criteria for both the ‘stomach’ and ‘stomach & 
intestine’ compartments. Under these conditions these results would indicate that the 
UBM method would be fit for purpose. 
 
4.6. Cadmium  
For Cd there are comparative data (Schroder et al., 2003) for five of the soils (Nb Cd1, 
NBR-255B-04, NBR-256-04, NBR-261-04, NBR-267-04) using the IVG bioaccessibility 
method discussed in Section 4.5. In a similar manner to As, for the ‘stomach’ 
compartment there is a strong 1:1 relationship with the UBM data (a simple linear 
regression with the UBM on the x-axis and OSU-IVG on the y axis gives rsquare = 0.86, 
slope = 0.97 and intercept = -0.4). For the ‘stomach & intestine’ compartment both 
methods give lower values than their equivalent ‘stomach compartments’ (t-test p-value 
<0.005) and there is a strong correlation between the UBM and the OSU-IVG although 
the latter gives, on average, lower values than the former (a simple linear regression with 
the UBM on the x-axis and OSU-IVG on the y axis gives rsquare = 0.71, slope = 0.59 and 
intercept = 4.3). 
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Table 5 shows a strong correlation of relative bioaccessible Cd with relative bioavailable 
Cd in the stomach compartment but the slope of the line is 0.63 which does not meet the 
benchmark criteria although this value is in agreement with the slope of the 
bioaccessibility vs relative bioavailability plot (0.60) using the OSU-IVG method 
(Schroder et al., 2003). Figure 5 shows the error bars on the on the relative 
bioaccessibility values to be less than the relative bioavailability error bars. Table 5 and 
Figure 5(e) show that the within and between-laboratory repeatability meet the 
benchmark criteria for the ‘stomach’ compartment. For the ‘stomach & intestine’ 
compartment, however, Table 5 and Figures 5(f) and 6(f) show that the slope, r-square, 
repeatability and reproducibility are degraded, so that all but the within-laboratory RSD 
fail the benchmark criteria. Under these conditions these results would indicate that, apart 
from the preferred slope of >0.8, the UBM method would be fit for purpose for the 
‘stomach’ phase but not the ‘stomach & intestine’ phase. The decreased slope of the 
regression line and the poorer reproducibility in the ‘stomach & intestine’ phase is 
probably related to the higher pH in this compartment. Cadmium solubility decreases at 
high pH (Cotton et al., 1999), the spike recovery (Figure 2) shows that Cd is lost to 
precipitation at pH 6.3 and complexation by pepsin in the gastro-intestinal compartment 
(Ellickson et al., 2001; Gron and Andersen, 2003), and similarly Cd extracted from the 
soil - at pH 1.2 will undergo the same processes in the ‘stomach & intestine’ phase.  In 
addition, the soil also provides a sink for sorption at the higher pH conditions which is 
dependent on individual soil properties. These include the amount of organic matter, clays 
and Al and Fe oxides present in the soil. All of these can act as sites for specific 
adsorption at neutral to alkaline pH (Cave et al., 2011). All of these effects result in a 
lower slope and poorer reproducibility. 
 
4.7. Lead  
Table 5 shows that the slope of the line for the ‘stomach’ compartment is only just below 
the benchmark criteria (0.78 compared with a target of 0.8) and the correlation with 
bioavailable Pb is within the criterion. Examination of Figure 5(g) and 5(h) and Table 3 
shows two groupings in the data, a set of 6 samples with relative bioaccessibilities of 10% 
or less and a set of 6 samples with relative bioaccessibilities 40% or greater. The former 
group of 6 samples are those that were only available to one laboratory and only have 
very low relative bioaccessibilities compared with their relative bioavailabilities. Figure 4 
shows that pH at the end of the ‘stomach’ phase was much higher than specified in the 
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procedure and this may account for the low bioaccessibility values in these samples. This 
hypothesis is also supported by comparison of the absolute bioaccessibility values from 
this study with the absolute bioaccessibility values obtained for these six soils using the 
IVG method (Schroder et al., 2004), which, unlike As and Cd, has poor correlation and 
very low values compared with the IVG stomach compartment. A simple linear 
regression with the UBM on the x-axis and IVG on the y axis gives rsquare = 0.19, slope 
= 2.3 and intercept = 14.2. There are no literature bioaccessibility data for comparison of 
the samples with relative bioaccessibilities >40% that were extracted by all participating 
laboratories. These samples, however, have relative bioaccessibilities which are more 
comparable to the relative bioavailability data (Figure 5(g)). Figure 6(g) and Table 5 
show that the within-laboratory repeatabilities for the stomach compartments are well 
within the benchmark criteria but the between-laboratory reproducibility is poor.   
 
Table 5 and Figures 5(h) and 6(h) show that none of the benchmark criteria are met for 
the ‘stomach & intestine’ compartment. The groupings observed in the ‘stomach’ 
compartment data are also seen in the ‘stomach & intestine’ compartment although less 
pronounced. The poor reproducibility and low slope at the higher pH of the ‘stomach & 
intestine’ are likely to be due the same effects described for Cd . 
 
5. Discussion 
For As, the low inter-laboratory RSDs and the high between-laboratory RSDs suggest 
that the small differences between the way the test is applied to these soils has a large 
effect on the results obtained. These soils have a complex physico-chemical composition 
and contain very high concentrations of As (Table 1) arising from the mining slag which 
forms a major part of their mass, which appears to contribute to the reproducibility 
problems observed in the inter-laboratory trial. This can also be seen in the very high 
uncertainty in the in vivo measurements (Figures 5(a) to 5(d)).  Variability in 
bioaccessible As can be reduced by careful control of in vitro pH which has been shown 
to greatly affect the measured metal bioaccessibility (Oomen et al., 2002; Yang et al., 
2003; Waisberg et al., 2004; Tang et al., 2006; Tang et al., 2007; Tang et al., 2008). 
However, pH cannot be controlled during in vivo dosing trials used to calculate the 
relative bioavailability of As in soil. Although the higher dilution test (soil to liquid ratio 
1:1000 g ml-1) was only carried out at two laboratories the soils produce results which 
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meet the benchmark criteria. Possible reasons why the higher dilution gives better results 
are: 
i) The higher dilution removes the problem of As oversaturation which may be the 
cause of the low slope and poorer reproducibility at low dilution;  
ii) At the higher dilution matrix effects (dissolution of concomitant chemical species 
from the sample, which adversely affect the chemical analysis) from the mine 
waste material are reduced. 
The drawback with using the 1:1000 g ml-1 soil to liquid ratio is that the small amount of 
sample may cause reproducibility problems if the test soil is inhomogeneous and, if soils 
with lower contamination concentrations are tested, the higher dilution may bring the 
concentrations of the analyte near to or below the method detection limit.   
 
In practical terms, contaminated materials that are relevant to human exposure scenarios 
where bioaccessibility measurements will have a significant effect on the risk assessment 
are soils with contaminants close to human health guideline values and not very highly 
contaminated mine wastes and slags similar to those assessed in this study.  When 
considering these soils, concentration of As will be far lower and the matrix effects much 
reduced and the problems encountered here are likely to be much reduced.  However, it is 
recognised that mine waste contaminated soils are important in human health risk 
assessments and that in these cases it may be more appropriate to use the 1:1000 g ml-1 
soil to liquid ratio. 
 
For Cd, the method meets all but the slope criteria for the specified benchmarks for the 
‘stomach’ phase (Table 5). The low slope and poor repeatability/reproducibility observed 
in the ‘stomach & intestine’ phase suggests that the Cd is precipitated out of solution at 
high pH causing the poor performance. 
 
The Pb data in the ‘stomach’ compartment for the samples extracted by all the 
laboratories shows reasonable agreement with the in vivo data but all of these soils have 
high relative bioavailable values (>50%). The relative bioaccessibility data from the 
samples with lower relative bioavailabilities is questionable because of the ‘stomach’ 
phase tolerances not being met on these samples. Table 5 shows Pb in the ‘stomach’ 
phase fits the rsquare and within-laboratory RSD criteria, and is only just outside the 
slope criteria (0.78, should be ≥0.8) and the between-laboratory RSD criteria (22.78, 
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should be ≤20). For the ‘stomach & intestine’ phase none of the criteria are met which, 
like Cd, suggests that precipitation at high pH causes the poor performance.       
 
This study suggests that pH control is a critical factor for obtaining between-laboratory 
reproducibility. Using tighter pH tolerance on the stomach phase (1.20 ±0.05), Caboche 
(2009) has shown that the UBM correlates well with in vivo swine data for As, Cd and Pb 
on 15 soils with different contamination histories (r-square values >0.89 and slopes not 
significantly different from 1). In this study, the repeatability of the average relative 
bioaccessible measurements for the 15 soils for the ‘stomach’ and the ‘stomach & 
intestine’ compartments were c.8% and 10% RSD for As, c.6 and 7% for Cd and c.5% 
and 5% for Pb. Using the UBM with a stomach phase at pH 1.5 ±0.05 on smelter 
contaminated agricultural topsoils (Pelfrene  et al., 2011), repeatabilities for the ‘stomach’ 
and the ‘stomach & intestine’ compartments of 1.5 and 2.2% RSD for Cd and 1.2 and 
2.2% RSD for Pb were demonstrated on 4 selected soils. These soils had absolute 
bioaccessible Cd values in the range of 0.8-24.7 mg kg-1 and Pb absolute bioaccessible 
values in the range of 84-1880 mg kg-1. Although not a true reproducibility study, the 
same authors demonstrated between operator repeatabilities for the ‘stomach’ and the 
‘stomach & intestine’ compartments of 3.4% and 15.2% RSD for Cd and 11.0% and 6.5% 
RSD for Pb using the same subset of soils. Without tighter pH control (stomach pH 1.2-
1.4), a study of urban soils contaminated from Pb, Zn smelters (Roussel et al.2010) 
showed repeatabilities for the UBM method for the ‘stomach’ and the ‘stomach & 
intestine’ compartments of 6.3% and 13.8% RSD for Cd and 12.0% and 17.4 % RSD for 
Pb for the NIST 2710 standard reference material (n=25). Whilst these studies are not 
directly comparable, there is some evidence that the studies (Caboche, 2009; Pelfrene  et 
al., 2011) with tighter controls on the stomach pH have better repeatabilities than the 
study (Roussel et al. 2010)with wider pH limits (< 10 % compared with 6-17% RSD) thus 
supporting the findings of this study. The between operator study (Pelfrene et al., 2011), 
although not strictly comparable to a between-laboratory comparison, shows RSD values 
<20%, again suggesting that the benchmark criteria of <20% RSD should be obtainable 
with careful control on the method.   
The overall purpose of a bioaccessibility test is to provide information for risk assessors 
on the amount of PHE will be taken into the body via the ingestion route. A validation 
study comparing in vitro and in vivo data is, in effect, calibrating the bioaccessibility 
against bioavailability data so that the more easily obtained bioaccessibility values can be 
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used to predict bioavailability. There are a number of uncertainties in relating a 
bioaccessible value to the amount of PHE absorbed by a human subject. If we assume the 
swine gastrointestinal model is a good surrogate for humans (Miller and Ullrey, 1987; 
Moughan et al., 1992) and that there is a linear relationship between bioaccessibility and 
bioavailability (Schroder et al., 2003; Schroder et al., 2004; Drexler and Brattin, 2007; 
Juhasz et al., 2007a) then the data from this and similar studies can be used to provide 
information on the reliability of the data provided to the risk assessor.  A simulation was 
set up using relative bioavailability data on a set of theoretical soils covering the range of 
1 to 90% (1, 5, 25, 50, 75 and 90%) with theoretical relative bioaccessibility data on the 
same soil samples. The simulation used a linear model with slope of unity and intercept of 
zero where bioavailability is to be predicted from bioaccessibility.  The uncertainties are 
normally distributed on both parameters ranging from 5% to 20% RSD. A Monte Carlo 
simulation was set up to estimate the uncertainties on the predicted bioavailability. The 
linear models for the slope and intercept were created using Theils method (Theil, 1950; 
Glaister, 2005) that accommodates errors on both the x and y axes. The results are shown 
in Figure 6 with error bars indicating 95% confidence intervals. At 5% RSD uncertainty 
on the bioaccessibility and bioavailability data used for the calibration all of the five 
bioavailability predictions (1, 5, 25, 75and 90% relative bioavailability) are all clearly 
distinguishable. At 10% RSD uncertainty the two highest and lowest predicted values 
have overlapping error bars but the intermediate bioavailability values are still clearly 
distinguishable. For 20% RSD uncertainty the overlap between the predicted values 
increases again but it is still possible to distinguish between 5%, 25% and 75% predicted 
bioavailability. In this study a reproducibility target of 20% has been set; however, Figure 
6 shows that the majority of within-laboratory RSD (method repeatability) are better than 
10% and therefore with more careful specification of the test (particularly pH control) it 
should be possible to approach 10% RSD reproducibility. This simulation clearly shows 
that 20% reproducibility is the maximum tolerable in order to provide useful data for risk 
assessment.  
The simulation also requires that the in vivo bioavailability data should also be better than 
20% RSD which may be more difficult to control. Figure 5 shows that the uncertainties 
on the bioavailability data are in many cases much higher than the bioaccessibility values 
and therefore improved in vivo data is also required to provide robust validation. The 
uncertainty simulation clearly shows that improvements in the reproducibility of both the 
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in-vivo and in-vitro measurements are required to give risk assessors more confidence in 
the use of bioaccessibility data.  
 
6. Conclusion 
In terms of meeting the five main criteria for the bioaccessibility test (listed in section 1), 
the UBM is physiologically based with one set of extraction reagents used for the three 
elements considered in this study. The As bioaccessibility measurements, however, 
required a lower solid to liquid ratio than for Cd and Pb. It is envisaged that this will not 
be necessary for contaminated soils with As concentrations that are more relevant to 
human exposure scenarios. The correlations between the in vivo data and the in vitro data 
suggest that the UBM is a good analogue of in vivo conditions although there is a need to 
improve the repeatability and reproducibility of the method before this can be clearly 
demonstrated. The test uses fasted conditions (low stomach pH with no food present) and 
is therefore likely to give conservative (high bioaccessible values) results, which has been 
confirmed by an independent study (Caboche, 2009) using a comparison against an in-
vivo swine model.. The UBM method does, however, agree well with the IVG in vitro 
test for As and Cd in the stomach compartments where data for the same soils are 
available. The IVG method has been validated against swine data for As, Cd and Pb 
(Schroder et al., 2003; Schroder et al., 2004; Basta et al., 2007). 
This study and others (Roussel et al.,2010 ; Caboche, 2009; Pelfrene  et al., 2011)that use 
the UBM have highlighted a number of specific aspects of the UBM test that need to be 
addressed. There needs to be a review of the practical procedures used in the in vitro test 
to improve the between-laboratory repeatability. Previous studies have shown the 
importance of pH of the ‘stomach’ compartment on the final bioaccessibility result 
(Oomen et al., 2002). It is possible that the pH tolerance for the UBM is too wide. This is 
probably one of the main sources of between-laboratory variability in this study. 
For As, it appears that the method will meet the benchmark criteria for both ‘stomach’ 
and ‘stomach & intestine’ compartments if soils with lower As concentrations (tens to 
hundreds of mg kg-1) and with a less complex physico-chemical make up are used. For Cd 
and Pb it seems possible that the method will work for the ‘stomach’ phase but not for the 
‘stomach & intestine’ phase; A further follow up study/inter-laboratory trial using test 
soils with contaminant concentrations more relevant to bioaccessibility testing (e.g. up to 
5 times soil guideline values) is required; The As soils provided by Professor Basta have 
a complex physico-chemical composition, which appears to contribute to the 
23 
 
reproducibility problems observed in the inter-laboratory trial; A more rigorous in vivo 
validation using fasted conditions of the UBM is required; It is not unusual for the first 
inter-laboratory trial of a new operationally defined procedure for extracting metals from 
soils to have some initial problems e.g. Quevauviller ( 2002), which is indeed the case for 
the UBM method. However, the data indicate that, in general, this in vitro test provides 
bioaccessibility data which is comparable data to in vivo bioavailability data. The study 
has highlighted areas of the test which require further refinement but it is our view that 
with further development this procedure provides a basis for a standardised 
bioaccessibility test for PHEs in soils.   
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Table 1 Summary of materials under investigation with published total and relative bioavailable 
concentrations.  Where relative bioavailability is the bioavailable fraction of the contaminant in 
the soil relative to the bioavailability of a soluble salt of the contaminant. 
Soil Total As    mg kg-1 
RBA As    
% 
Total Cd      
mg kg-1 
RBA Cd     
% 
Total 
Pb       
mg kg-1 
RBA 
Pb     
% 
Material Type 
As 1 11300 8.62 n/a n/a n/a n/a Calcine Soils(Rodriguez et al., 1999; Basta et al., 2007) 
As 2 17500 4.07 n/a n/a n/a n/a As above 
As 3 13500 7.88 n/a n/a n/a n/a As above 
As 4 11500 22.8 n/a n/a n/a n/a As above 
As 6 405 38.7 n/a n/a n/a n/a Iron Slag Soils (Rodriguez et al., 1999; Basta et al., 2007)) 
As 7 450 43 n/a n/a n/a n/a As above 
As 8 1180 39.1 n/a n/a n/a n/a As above 
As 9 5020 32.9 n/a n/a n/a n/a As above 
As 10 4650 21.9 n/a n/a n/a n/a As above 
AR 1 676 37 n/a n/a n/a n/a Aberjona River Sediments 
AR 2 313 51 n/a n/a n/a n/a As above 
ETM 1 n/a n/a 4109 60 n/a n/a Pt. Mugu Soil 1B 
ETM 2 n/a n/a 452 89 n/a n/a CO-SCS Soil 
ETM 3 n/a n/a 102 79 n/a n/a OK-SS Soil 
ETM 4 n/a n/a 46.8 18 n/a n/a Dugway Soil #4 
NB Cd1 n/a n/a 465 55.4 n/a n/a Nick Basta Cd Study sample 1, Blackwell Soil  (Schroder et al., 2003; 2007) 
NBR-255B-04 n/a n/a 188 53.6 4050 90 
Nick Basta Pb-Cd studies samples 5 and 4, 
Jasper Yard soil (Schroder et al., 2003; 
2007) 
NBR-256-04 n/a n/a 29.9 10.4 11700 40 
Nick Basta Pb-Cd studies samples 12 and 
6, Murray Slag (Schroder et al., 2003; 
2007) 
NBR-261-04 n/a n/a 43 29.9 8530 14 Nick Basta Pb-Cd studies samples 2 and 2, Butte NPL  (Schroder et al., 2003; 2007) 
NBR-267-04 n/a n/a 23.8 56.8 3200 51 
Nick Basta Pb-Cd studies samples 13 and 
7, Murray Soil  (Schroder et al., 2003; 
2007) 
NBPb 11 n/a n/a n/a n/a 8170 14 Nick Basta Pb study sample 11, Midvale Slag Soil  (2007) 
NBPb 9 n/a n/a n/a n/a 10600 20 Nick Basta Pb study sample 9, Leadville Slag Soil  (2007) 
B & V 1A n/a n/a n/a n/a 1650 102 Composite Soil 
B & V 1B n/a n/a n/a n/a 1630 75 Composite Soil 
B & V 2 TM1 n/a n/a n/a n/a 2280 52 House Dust 
B & V 2 TM2 n/a n/a n/a n/a 2310 97 Composite Soil 
DNR5 1 n/a n/a n/a n/a 2830 99 0.5 % Phosphate-treated soil 
DNR5 2 n/a n/a n/a n/a 4230 76 1 %  Phosphate-treated Soil 
MSE2 n/a n/a n/a n/a 2020 82 Soil 
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Table 2 Summary data for mean and standard deviation for the relative bioaccessibilities 
of As in the test samples using the UBM in vitro method. Where “st” is the stomach 
compartment and  “st+int” is the stomach followed by intestinal compartment  
Sample Name 
Number of data 
points 
Relative 
Bioaccessibility 
(%) 
Standard 
deviation (%) 
Soil:solution 
ratio (g ml-1) Compartment 
As 1 7 1.6 0.4 0.01 st 
As 2 7 1.2 0.3 0.01 st 
As 3 7 2.5 0.7 0.01 st 
As 4 7 5.0 1.6 0.01 st 
As 6 7 24.3 10.0 0.01 st 
As 7 7 25.7 13.1 0.01 st 
As 8 7 27.3 20.4 0.01 st 
As 9 6 23.8 15.6 0.01 st 
As 10 7 17.7 6.0 0.01 st 
AR 1 2 10.7 0.7 0.01 st 
AR 2 2 25.8 11.0 0.01 st 
As 1 7 1.8 0.3 0.01 st+int 
As 2 7 1.3 0.3 0.01 st+int 
As 3 7 2.6 0.6 0.01 st+int 
As 4 7 5.1 1.3 0.01 st+int 
As 6 7 8.3 5.4 0.01 st+int 
As 7 7 6.6 5.4 0.01 st+int 
As 8 7 5.3 3.7 0.01 st+int 
As 9 6 7.7 4.8 0.01 st+int 
As 10 7 6.3 5.0 0.01 st+int 
AR 1 2 6.7 0.7 0.01 st+int 
AR 2 2 19.2 7.2 0.01 st+int 
As 1 7 1.9 0.2 0.001 st 
As 2 7 1.4 0.1 0.001 st 
As 3 7 2.6 0.2 0.001 st 
As 4 7 5.5 0.2 0.001 st 
As 6 7 44.3 2.5 0.001 st 
As 7 7 48.9 14.6 0.001 st 
As 8 7 40.7 2.3 0.001 st 
As 9 6 37.1 0.8 0.001 st 
As 10 7 24.1 1.6 0.001 st 
As 1 7 2.0 0.5 0.001 st+int 
As 2 7 1.4 0.3 0.001 st+int 
As 3 7 2.9 0.7 0.001 st+int 
As 4 7 5.9 1.7 0.001 st+int 
As 6 7 58.4 8.2 0.001 st+int 
As 7 7 48.1 4.3 0.001 st+int 
As 8 7 33.3 5.1 0.001 st+int 
As 9 6 31.1 2.5 0.001 st+int 
As 10 7 22.5 0.6 0.001 st+int 
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Table 3 Summary data for mean and standard deviation for the relative bioaccessibilities 
of Cd and Pb in the test samples using the UBM in vitro method (soil: solution ratio of 
0.01 g ml-1 for all samples). Where “st” is the stomach compartment and “st+int” is the 
stomach followed by intestinal compartment. 
 
Sample Name Element 
Number 
of data 
points 
Relative 
Bioaccessibility 
(%) 
Standard 
Deviation (%) Compartment 
ETM 1 Cd 6 86.4 4.5 st 
ETM 2 Cd 6 85.6 5.7 st 
ETM 3 Cd 6 83.2 4.8 st 
ETM 4 Cd 7 36.0 3.0 st 
NB Cd 1 Cd 3 67.8 4.3 st 
NBR-255B-04 Cd 1 48.4 3.0 st 
NBR-256-04 Cd 1 45.6 2.8 st 
NBR-261-04 Cd 1 24.2 1.5 st 
NBR-267-04 Cd 1 70.7 4.0 st 
ETM 1 Cd 6 41.9 31.0 st+int 
ETM 2 Cd 6 75.5 19.5 st+int 
ETM 3 Cd 6 107.2 51.3 st+int 
ETM 4 Cd 7 32.1 13.3 st+int 
NB Cd 1 Cd 3 69.9 3.4 st+int 
NBR-255B-04 Cd 1 53.7 24.0 st+int 
NBR-256-04 Cd 1 49.5 22.1 st+int 
NBR-261-04 Cd 1 17.1 7.6 st+int 
NBR-267-04 Cd 1 55.9 22.8 st+int 
B & V 1A Pb 6 112.8 18.5 st 
B & V 1B Pb 7 84.5 19.0 st 
B & V 2TM1 Pb 7 45.2 18.7 st 
B & V 2TM2 Pb 7 85.5 19.8 st 
DNR5-1 Pb 7 59.0 20.6 st 
DNR5-2 Pb 7 46.0 18.8 st 
MSE 2 Pb 6 85.4 6.6 st 
NB Pb 11 Pb 1 0.6 0.1 st 
NB Pb 9 Pb 1 0.9 0.2 st 
NBR-255B-04 Pb 1 11.6 2.7 st 
NBR-256-04 Pb 1 6.9 1.6 st 
NBR-261-04 Pb 1 10.3 2.4 st 
NBR-267-04 Pb 1 3.2 0.7 st 
B & V 1A Pb 6 89.5 91.3 st+int 
B & V 1B Pb 7 43.4 33.3 st+int 
B & V 2TM1 Pb 7 20.8 7.3 st+int 
B & V 2TM2 Pb 7 57.6 36.4 st+int 
DNR5-1 Pb 7 30.1 24.9 st+int 
DNR5-2 Pb 7 15.4 14.2 st+int 
MSE 2 Pb 6 54.0 38.1 st+int 
NB Pb 11 Pb 1 1.2 1.5 st+int 
NB Pb 9 Pb 1 1.2 1.6 st+int 
NBR-255B-04 Pb 1 12.3 16.1 st+int 
NBR-256-04 Pb 1 8.8 11.4 st+int 
NBR-261-04 Pb 1 0.1 0.1 st+int 
NBR-267-04 Pb 1 4.6 6.0 st+int 
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Table 4 Summary data for the bioaccessible fraction of the Quality Control samples from 
each of the participating laboratories. The mean value is in mg kg-1, the relative standard 
deviations (RSD) are expressed as %, “st” is the stomach compartment and  “st+int” is the 
stomach followed by intestinal compartment 
 
Measurement NIST 
2710  
NIST 
2711 
BGS 
102 
Element Compartment S:L g ml-1 
Overall mean 323 55.1 4.52 As st 0.01 
Repeatability RSD 5.53 3.23 26.7 As st 0.01 
Reproducibility RSD 13.8 11.0 28.2 As st 0.01 
Overall mean 335  -  - As st 0.001 
Repeatability RSD 7.80  -  - As st 0.001 
Reproducibility RSD 9.14  -  - As st 0.001 
Overall mean 264 45.6 5.38 As st+int 0.01 
Repeatability RSD 0.63 8.55 35.7 As st+int 0.01 
Reproducibility RSD 6.89 22.0 44.5 As st+int 0.01 
Overall mean 316  -  - As st+int 0.001 
Repeatability RSD 13.3  -  - As st+int 0.001 
Reproducibility RSD 16.0  -  - As st+int 0.001 
Overall mean 14.8 33.8 0.281 Cd st 0.01 
Repeatability RSD 5.83 2.58 29.9 Cd st 0.01 
Reproducibility RSD 7.36 9.24 60.3 Cd st 0.01 
Overall mean 7.86 16.2 0.593 Cd st+int 0.01 
Repeatability RSD 21.7 7.20 46.5 Cd st+int 0.01 
Reproducibility RSD 23.0 29.20 89.0 Cd st+int 0.01 
Overall mean 3785 958 12.8 Pb st 0.01 
Repeatability RSD 5.54 2.73 13.3 Pb st 0.01 
Reproducibility RSD 12.4 2.96 46.8 Pb st 0.01 
Overall mean 1138 101 3.11 Pb st+int 0.01 
Repeatability RSD 44.2 40.8 139 Pb st+int 0.01 
Reproducibility RSD 80.0 94.6 141 Pb st+int 0.01 
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Table 5 Summary of method assessment criteria, grey highlights pass the benchmark 
criteria 
Element 
Liquid to 
solid 
ratio 
(ml g-1) Compartment r2 r slope 
Median 
within 
RSD 
Median 
Between 
RSD 
As 100 st 0.77 0.88 0.40 5.70 29.47 
As 100 st+int 0.63 0.80 0.16 6.92 25.94 
As 1000 st 0.91 0.95 0.89 3.83 7.43 
As 1000 st+int 0.83 0.91 0.88 7.26 15.72 
Cd 100 st 0.69 0.83 0.63 3.90 7.00 
Cd 100 st+int 0.51 0.71 0.57 9.16 35.32 
Pb 100 st 0.61 0.78 0.78 3.59 22.78 
Pb 100 st+int 0.57 0.76 0.38 14.62 81.39 
                
Units           % % 
Criteria     ≥0.6 ≥0.77 ≥0.8 ≤10 ≤20 
 
 
 
35 
 
 
 
Figure 1 –Schematic of the UBM (full details of how the method was used in the inter-
laboratory study are given in sections 3.2 and 4.4) 
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Figure 2 Box and whisker plot summarising the percentage recoveries of As, Cd and Pb 
in the spiked stomach and stomach & intestine phase solutions at the standard 
soil:solution ratio (1:100 g ml-1) 
37 
 
 
 
As 1 As 2 As 3 As 4 As 5 As 6 As 7 As 8 As 9 As 10 AR 1 AR 2
1.5
2
2.5
3
3.5
4
4.5
En
d 
St
om
ac
h 
pH
 
 
Figure 3 pH tolerance data for the ‘stomach’ phase of the UBM for the As soils under 
investigation. The dashed horizontal lines indicate the pH tolerance at the end of the 
stomach phase extraction 
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Figure 4 pH tolerance data for the ‘stomach’ phase of the UBM for the Cd and Pb soils 
under investigation. The dashed lines indicate the pH tolerance at the end of the stomach 
phase extraction. 
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 Figure 5 Relative bioaccessibility vs in vivo relative bioavailability for As Cd and Pb in 
the stomach and stomach and intestine compartments and associated soil:solution ratios.  
The solid black line shows the median straight line fit, the dotted line shows the line of 
equivalence and the dashed lines represent the 90% confidence region. 
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Figure 6 Summary plots of the relative standard deviation (RSD) for As, Cd and Pb for 
the between-laboratory (o) and within-laboratory (+) bioaccessibility measurements in the 
stomach and intestine compartments at associated soil:solution ratios.  The x-axis 
represents the bioaccessible value in mg kg-1 and the y axis represents the RSD as a 
percentage.  Dashed horizontal lines show 10% and 20% RSD. 
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Figure 7 Effect of increasing uncertainty in the bioaccessibility and bioavailability 
calibration data on the predicted bioavailability. Y axis data have had small shift 
introduced to so that overlap of error bars can be clearly viewed.   
 
 
